Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.52 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320483 | 1.00 | PTGS2 (0.52) | PTGS2ACHEBCHEBACE1KDR | |
| SCHEMBL4322602 | 0.83 | MAPT (0.47) | KDRAURKAAURKBMAPTFGFR1 | |
| SCHEMBL4322598 | 0.83 | MAPT (0.47) | KDRAURKAAURKBMAPTFGFR1 | |
| SCHEMBL4315404 | 0.82 | NPC1 (0.50) | AURKAAURKBMAPT | |
| SCHEMBL4315408 | 0.82 | NPC1 (0.50) | AURKAAURKBMAPT | |
| SCHEMBL4316960 | 0.80 | KDR (0.47) | KDRAURKAAURKBFGFR1 | |
| SCHEMBL4316962 | 0.80 | KDR (0.47) | KDRAURKAAURKBFGFR1 | |
| SCHEMBL4312113 | 0.80 | KDR (0.46) | KDRAURKAAURKBFGFR1 | |
| SCHEMBL4315416 | 0.80 | AURKA (0.41) | KDRAURKAAURKBMAPTFGFR1 | |
| SCHEMBL4315409 | 0.80 | AURKA (0.41) | KDRAURKAAURKBMAPTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | PTGS2 4420/4885ACHE 4528/4885BCHE 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.